nach oben

International Journal of Diabetes in Developing Countries

Erschienen in:

01.04.2011 | Letter to Editor

Once-weekly exenatide in type 2 diabetes

verfasst von: Dinesh M. Parmar, Shilpa P. Jadav

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Excerpt

Sir, …

Bosi E, Lucotti P, Setola E, Monti L, Piatti PM. Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes Res Clin Pract. 2008;82 Suppl 2:102–7.CrossRef

Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281:E155–61.PubMed

Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep. 2010;10:124–32.PubMedCrossRef

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet. 2008;372:1240–50.

Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hao Hu H, et al. for the DURATION-1 Study Group. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss Over 52 Weeks. Diab Care 2010 Mar 9 [Epub ahead of print].

Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376:431–39.

Diamant M, Gaal LV, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomized trial. Lancet. 2010;375:2234–43.PubMedCrossRef

Misra A, Joshi S. Longacting exenatide in diabetes: DURATION-3. Lancet. 2010;375:2198–99.PubMedCrossRef

DURATION-4 Study results: Bydureon efficacy and tolerability profile extended to monotherapy treatment. [homepage on the Internet]. San Diego, Indianapolis, Waltham: Amylin Pharmaceuticals, Inc., Eli Lilly and Company; Alkermes, Inc. [cited 2010 Jun 15]. Available from: http://newsroom.lilly.com/releasedetail.cfm?releaseid=479567.

Titel: Once-weekly exenatide in type 2 diabetes
verfasst von: Dinesh M. Parmar
Shilpa P. Jadav
Publikationsdatum: 01.04.2011
Verlag: Springer-Verlag
Erschienen in: International Journal of Diabetes in Developing Countries / Ausgabe 2/2011
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-011-0018-2

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Genetic etiology of type 2 diabetes mellitus: a review

Effect of human umbilical cord blood CD34+ progenitor cells transplantation in diabetic mice

Early remission of type 2 diabetes mellitus by laparoscopic ileal transposition with sleeve gastrectomy surgery in 23–35 BMI patients

Islet cell autoantibodies in patients younger than 20 years of age with recently diagnosed diabetes in Northwest of Iran

Difference in prevalence of diabetes, obesity, metabolic syndrome and associated cardiovascular risk factors in a rural area of Tamil Nadu and an urban area of Delhi

Efficacy of ethanolic extract of ginger on kidney lipid metabolic profiles in diabetic rats